Eli Lilly submits tirzepatide for approval in US and EU

Both the FDA and EMA have accepted Eli Lilly's marketing approval applications for its type 2 diabetes treatment, tirzepatide, the US-based pharmaceutical firm announces, also reporting that applications for seven additional markets have been submitted.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Eli Lilly's tirzepatide, presumably the biggest contender for Novo Nordisk's newest generation of diabetes drugs, has taken a pivotal step on the pathway toward future market launches.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading